Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | AGXT | P21549 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.44 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4784337 | 0.85 | PIN1 (0.54) | LOXL2AGXTFLT3PIN1NPC1 | |
| SCHEMBL7888402 | 0.85 | PIN1 (0.54) | LOXL2AGXTFLT3PIN1NPC1 | |
| Hydrochloric Acid SCHEMBL8578217 | 0.84 | PIN1 (0.53) | LOXL2AGXTFLT3PIN1NPC1 | |
| SCHEMBL26987879 | 0.82 | SLC1A5 (0.46) | LOXL2ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL27134734 | 0.82 | SLC1A5 (0.46) | LOXL2ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL7248298 | 0.76 | LOXL2 (0.53) | LOXL2AGXTFLT3PIN1NPC1 | |
| SCHEMBL7140949 | 0.75 | LOXL2 (0.56) | LOXL2AGXTFLT3NPC1RAB9A | |
| SCHEMBL29622317 | 0.74 | LOXL2 (0.55) | LOXL2AGXTHTR2BSMN1; SMN2HTR1A | |
| SCHEMBL10368235 | 0.74 | LOXL2 (0.55) | LOXL2AGXTFLT3PIN1NPC1 | |
| SCHEMBL23804835 | 0.74 | CYP1A2 (0.51) | LOXL2AGXTFLT3NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7888330-B2 | Phosphoramidate derivatives of FAU | WAYNE STATE UNIVERSITY (US) | 2011-02-15 | — | — | US | disclosed |
| US-20080292553-A1 | Phosphoramidate Derivatives of Fau | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-11-27 | — | — | US | disclosed |
| WO-2008073450-A2 | BENZAMIDE COMPOUNDS | GEORGETOWN UNIVERSITY (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2007056596-A2 | PHOSPHORAMIDATE DERIVATIVES OF FAU | WAYNE STATE UNIVERSITY (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20060194814-A1 | Benzamide compounds | GEORGETOWN UNIVERSITY | 2006-08-31 | — | — | US | disclosed |
| US-20060194815-A1 | Methods and compositions for modulating serum cortisol levels | GEORGETOWN UNIVERSITY | 2006-08-31 | — | — | US | disclosed |
| WO-2005112922-A9 | BENZAMIDE COMPOUNDS | SAMARITAN PHARMACEUTICALS (US) | 2006-03-09 | — | — | WO | disclosed |
| EP-1631289-A2 | ANTI-HIV BENZAMIDE COMPOUNDS | Samaritan Pharmaceuticals, Inc. (US) | 2006-03-08 | — | — | EP | disclosed |
| EP-1628660-A2 | METHODS AND COMPOSITIONS FOR MODULATING SERUM CORTISOL LEVELS | Samaritan Pharmaceuticals, Inc. (US) | 2006-03-01 | — | — | EP | disclosed |
| WO-2005112922-A2 | BENZAMIDE COMPOUNDS | SAMARITAN PHARMACEUTICALS (US) | 2005-12-01 | — | — | WO | disclosed |
| WO-2005000205-A2 | METHODS AND COMPOSITIONS FOR MODULATING SERUM CORTISOL LEVELS | SAMARITAN PHARMACEUTICALS, INC. (US) | 2005-01-06 | — | — | WO | disclosed |
| WO-2004108076-A2 | ANTI-HIV BENZAMIDE COMPOUNDS | SAMARITAN PHARMACEUTICALS, INC. (US) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194815-A1 | Methods and compositions for modulating serum cortisol levels | CRH, SERPINA6, BCHE | LOXL2 2042/4885AGXT 987/4885FLT3 4870/4885 |
| US-20080292553-A1 | Phosphoramidate Derivatives of Fau | DUT, FAU, DPYD | LOXL2 4742/4885AGXT 2182/4885FLT3 505/4885 |
| US-20060194814-A1 | Benzamide compounds | PIGS, BCAT2, GBA1 | LOXL2 2848/4885AGXT 1578/4885FLT3 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.